Stacha F. I. Reumers

Stacha F. I. Reumers

Auto-generated profile, based on publicly available information

Stacha F. I. Reumers

Department of Neurology, Radboud University Medical Centre, Donders Institute for Brain, Cognition, and Behaviour, Nijmegen, the Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2025 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
SRStacha F. I. Reumers
Stacha F. I. Reumers
FBFleur L. P. Bongaerts
Fleur L. P. Bongaerts
FLFrank-Erik de Leeuw
Frank-Erik de Leeuw
BWBart P. C. van de Warrenburg
Bart P. C. van de Warrenburg
DSDennis J. L. G. Schutter
Dennis J. L. G. Schutter
Roy P. C. KesselsRoy P. C. Kessels
Roy P. C. Kessels
Objective: This systematic review and meta-analysis aim to examine the profile and extent of cognitive deficits in patients with cerebellar disorders, and to provide a complete overview of the cognitive domains that might be affected in the Cerebellar Cognitive Affective Syndrome (CCAS). Methods: MEDLINE, Embase, PsycINFO, and Web of Science were systematically searched to 17-07-2024. Studies were considered if the participants were adult patients with a clinical diagnosis of cerebellar disorder and were neuropsychological assessed. Outcomes were grouped into the domains of processing speed, language, social cognition, executive function, visuospatial skills, episodic memory, verbal intelligence, attention, and working memory. All aetiologies were included for first evaluation and patients were assigned to one of two groups (focal vs. degenerative) for secondary evaluation. Random-effects models were employed for the meta-analyses. Results: 129 studies with a total of 3140 patients with cerebellar disorders were included. Patients performed significantly worse compared to control/standardized data in all domains. Deficits were most pronounced in processing speed, ES [95% CI] = − 0.83 [− 1.04, − 0.63], language, ES [95% CI] = − 0.81 [− 0.94, − 0.67], and social cognition, ES [95% CI] = − 0.81 [− 1.19, − 0.42]. Cognitive impairment varied between patients with focal cerebellar lesions and degenerative cerebellar disorders, but was overall worse in the degenerative group. Discussion: Cerebellar disorders can impact many cognitive domains, extending beyond executive functioning, visuospatial skills, and language. These outcomes contribute to a broader understanding of the cerebellum's role in cognition and sheds light on the cognitive deficits associated with cerebellar disorders.

3 August 2021 in Neurology
Verified
Journal Article
Open access
PDF file
SRStacha F.I. Reumers
Stacha F.I. Reumers
FBFrederik Braun
Frederik Braun
JSJennifer E. Spillane
Jennifer E. Spillane
JBJohann Böhm
Johann Böhm
MPMaartje Pennings
Maartje Pennings
NVNicol Voermans
Nicol Voermans
Objective To characterize the spectrum of clinical features in a cohort of X-linked myotubular myopathy (XL-MTM) carriers, including prevalence, genetic features, clinical symptoms, and signs, as well as associated disease burden. Methods We performed a cross-sectional online questionnaire study among XL-MTM carriers. Participants were recruited from patient associations, medical centers, and registries in the United Kingdom, Germany, and the Netherlands. We used a custom-made questionnaire, the Checklist Individual Strength (CIS), the Frenchay Activities Index (FAI), the Short Form 12 (SF-12) health survey, and the McGill Pain Questionnaire. Carriers were classified as manifesting or nonmanifesting on the basis of self-reported ambulation and muscle weakness. Results The prevalence of manifesting carriers in this study population (n = 76) was 51%, subdivided into mild (independent ambulation, 39%), moderate (assisted ambulation, 9%), and severe (wheelchair dependent, 3%) phenotypes. In addition to muscle weakness, manifesting carriers frequently reported fatigue (70%) and exercise intolerance (49%). Manifesting carriers scored higher on the overall CIS (p = 0.001), the fatigue subscale (p < 0.001), and least severe pain subscale (p = 0.005) than nonmanifesting carriers. They scored lower on the FAI (p = 0.005) and the physical component of the SF-12 health survey (p < 0.001). Conclusions The prevalence of manifesting XL-MTM carriers may be higher than currently assumed, most having a mild phenotype and a wide variety of symptoms. Manifesting carriers are particularly affected by fatigue, limitations of daily activities, pain, and reduced quality of life. Our findings should increase awareness and provide useful information for health care providers and future clinical trials.

31 August 2021 in Clinical Genetics
Verified
Journal Article
Open access
PDF file
SRStacha F. I. Reumers
Stacha F. I. Reumers
CECorrie E. Erasmus
Corrie E. Erasmus
KBKarlijn Bouman
Karlijn Bouman
MPMaartje Pennings
Maartje Pennings
MSMeyke Schouten
Meyke Schouten
NVNicol Voermans
Nicol Voermans
Centronuclear myopathy (CNM) is a genetically heterogeneous congenital myopathy characterized by muscle weakness, atrophy, and variable degrees of cardiorespiratory involvement. The clinical severity is largely explained by genotype (DNM2, MTM1, RYR1, BIN1, TTN, and other rarer genetic backgrounds), specific mutation(s), and age of the patient. The histopathological hallmark of CNM is the presence of internal centralized nuclei on muscle biopsy. Information on the phenotypical spectrum, subtype prevalence, and phenotype–genotype correlations is limited. To characterize CNM more comprehensively, we retrospectively assessed a national cohort of 48 CNM patients (mean age = 32 ± 24 years, range 0–80, 54% males) from the Netherlands clinically, histologically, and genetically. All information was extracted from entries in the patient's medical records, between 2000 and 2020. Frequent clinical features in addition to muscle weakness and hypotonia were fatigue and exercise intolerance in more mildly affected cases. Genetic analysis showed variants in four genes (18 DNM2, 14 MTM1, 9 RYR1, and 7 BIN1), including 16 novel variants. In addition to central nuclei, histologic examination revealed a large variability of myopathic features in the different genotypes. The identification and characterization of these patients contribute to trial readiness.

15 November 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
DFDaniëlle K. Franken
Daniëlle K. Franken
KBKarlijn Bouman
Karlijn Bouman
SRStacha F. I. Reumers
Stacha F. I. Reumers
FBFrederik Braun
Frederik Braun
JSJennifer Spillane
Jennifer Spillane
NVNicol Voermans
Nicol Voermans
Background X-linked myotubular myopathy (XL-MTM) is an early onset congenital myopathy characterized by mild to severe muscle weakness in males. Objective To characterize the clinical spectrum of neuromuscular features in X-linked myotubular myopathy (XL-MTM) carriers. Methods We performed a nationwide cross-sectional study focusing on neuromuscular features in an unselected cohort of Dutch XL-MTM carriers. Participants were recruited from neuromuscular centres in the Netherlands and through the Dutch and European patient associations. Genetic results were collected. Carriers were classified based on ambulatory status and muscle weakness. We used a questionnaire focussing on medical and family history and neuromuscular symptoms. Additionally, we performed a neurological examination including Manual Muscle Testing (MMT), Timed Up and Go test (TUG), and 6 Minutes Walking Test (6MWT). Results We included 21 carriers (20 genetically confirmed and one obligate), of whom eleven (52%) carriers were classified as manifesting, with severe (non-ambulatory; n=2), moderate (minimal independent ambulation/assisted ambulation; n=2), mild (independent ambulation but with limb or axial muscle weakness; n=3) and minimal (only facial muscle weakness, n=4) phenotypes. Three of the manifesting carriers (two severe, one moderate) were from families without genetically confirmed male XL-MTM patients. Furthermore, seven manifesting carriers (one moderate; two mild; four minimal) were not classified as manifesting carriers before participation in our study. Three carriers reported a history of pneumothorax. The obstetric history revealed frequent polyhydramnios (50%) and reduced fetal movements (36%) in pregnancies of affected sons. Muscle weakness was most pronounced in proximal and limb girdle muscles. Other frequently reported sign included (asymmetric) facial weakness (73%), reduced or absent deep tendon reflexes (45%), scoliosis (40%), and ptosis (45%). Ten participants (48%) were classified as non-manifesting. Manifesting carriers had lower functional testing scores on 6MWT and TUG compared to non-manifesting carriers. Discussion This study showed that 52% of an unselected group of XL-MTM carriers has muscle weakness (three of whom previously unclassified as manifesting). This corresponds to findings of our recent questionnaire study on self-reported symptoms in XLMTM carriers. These observations should raise awareness of the neuromuscular manifestations of the XL-MTM carrier state, and provide important epidemiological information required for future clinical trials.

2 July 2024 in Cortex
Verified
Journal Article
Open access
SRStacha F.I. Reumers
Stacha F.I. Reumers
MSMijntje M.I. Schellekens
Mijntje M.I. Schellekens
SLSelma Lugtmeijer
Selma Lugtmeijer
RMRoderick Maas
Roderick Maas
JVJamie I. Verhoeven
Jamie I. Verhoeven
IWIdo R. van Den Wijngaard
Ido R. van Den Wijngaard
Introduction: Cognitive impairment is a well-known result of a stroke, but for cerebellar stroke in young patients detailed knowledge on the nature and extent of cognitive deficits is limited. This study examined the prevalence and course of cognitive impairment in a large cohort of patients with cerebellar stroke. Methods: Sixty young (18–49 years) cerebellar stroke patients completed extensive neuropsychological assessments in the subacute (<9 months post-stroke) and/or chronic phase (≥9 months post-stroke). Performance and course were assessed using standardized scores and Reliable Change Index analyses. Associations between cognitive deficits and lesion locations were explored using subtraction analyses, and associations with subjective cognitive complaints and fatigue were examined. Results: Sixty patients (52% male) were included with a mean age at event of 43.1 years. Cognitive impairment was observed in 60.3% of patients in the subacute phase and 51.2% during the chronic phase. Deficits were most frequent for visuo-spatial skills and executive functioning (42.5–54.6%). Both improvement and decline were observed over time, in 17.9% and 41.0% of participants, respectively. Cognitive deficits seem to be associated with lesions in certain cerebellar regions, however, no distinct correlation was found for a specific subregion. Subjective cognitive complaints were present in the majority of participants (61–80.5%) and positively correlated with fatigue in both phases (ρ = −.661 and ρ = −.757, p < .001, respectively). Discussion: Cognitive impairment in cerebellar stroke patients is common, with deficits most pronounced for visuo-spatial skills and executive functioning, as in line with the Cerebellar Cognitive Affective Syndrome. The course of cognitive performance was heterogenous, with cognitive decline despite the fact that no recurrent strokes occurred. No clear association between lesion location and cognitive deficits was observed. Subjective cognitive complaints and fatigue were prevalent and positively correlated. Clinicians could use this information to actively screen for and better inform patients about possible cognitive sequalae.

2 November 2024 in Movement Disorders
Verified
Journal Article
Open access
SRStacha F.I. Reumers
Stacha F.I. Reumers
RMRoderick Maas
Roderick Maas
DSDennis J.L.G. Schutter
Dennis J.L.G. Schutter
STSteven Teerenstra
Steven Teerenstra
RKRoy P.C. Kessels
Roy P.C. Kessels
BWBart P.C. van de Warrenburg
Bart P.C. van de Warrenburg
Background: The cerebellar cognitive affective syndrome (CCAS) encompasses cognitive and affective symptoms in patients with cerebellar disorders, for which no proven treatment is available.Objectives: Our primary objective was to study the effect of cerebellar anodal transcranial direct current stimulation (tDCS) on cognitive performance in CCAS patients. Secondary effects on ataxia severity, mood, and quality of life were explored.Methods: We performed a randomized, double‐blind, sham‐controlled trial. Thirty‐five patients with CCAS were included and received 10 sessions of 20 minutes sham (n = 17) or real (n = 18) tDCS, with a current of 2 mA. Cognitive performance was assessed using executive function subtests of the computerized Test of Attentional Performance (TAP), with the composite as primary endpoint. Secondary outcomes were ataxia severity, mood, and quality of life. Outcomes were evaluated 1, 3, 6, and 12 months post‐intervention.Results: Cerebellar tDCS was well tolerated and no serious adverse events related to the intervention occurred. No significant tDCS effect was found on cognitive performance. Improvement on the TAP was observed in the sham group 1 month post‐treatment (estimate = −0.248, 95% CI, −0.49 to −0.01), but not clinically relevant. A positive tDCS effect was observed for ataxia severity 1 month post‐treatment (estimate = −0.985, 95% CI, −1.94 to −0.03).Conclusions: Ten sessions of 20 minutes cerebellar anodal tDCS did not prove efficacious for CCAS‐related cognitive impairment, but a significant positive effect of tDCS was found for ataxia severity, aligning with previous findings indicative of tDCS as a therapeutic neuromodulation tool in cerebellar disorders. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.